U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07341867) titled 'Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype' on Dec. 15, 2025.
Brief Summary: This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients w...